CN105828831A - 新型肽组合物 - Google Patents

新型肽组合物 Download PDF

Info

Publication number
CN105828831A
CN105828831A CN201480066852.9A CN201480066852A CN105828831A CN 105828831 A CN105828831 A CN 105828831A CN 201480066852 A CN201480066852 A CN 201480066852A CN 105828831 A CN105828831 A CN 105828831A
Authority
CN
China
Prior art keywords
peptide
body weight
xaa
pharmaceutical composition
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480066852.9A
Other languages
English (en)
Chinese (zh)
Inventor
R·弗兰克林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tarix Pharmaceuticals Ltd
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of CN105828831A publication Critical patent/CN105828831A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201480066852.9A 2013-10-11 2014-10-01 新型肽组合物 Pending CN105828831A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361890056P 2013-10-11 2013-10-11
US61/890,056 2013-10-11
US201461940095P 2014-02-14 2014-02-14
US61/940,095 2014-02-14
PCT/US2014/058646 WO2015054006A2 (en) 2013-10-11 2014-10-01 Novel peptide compositions

Publications (1)

Publication Number Publication Date
CN105828831A true CN105828831A (zh) 2016-08-03

Family

ID=52813728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480066852.9A Pending CN105828831A (zh) 2013-10-11 2014-10-01 新型肽组合物

Country Status (13)

Country Link
EP (1) EP3054967A4 (enExample)
JP (1) JP2017501967A (enExample)
KR (1) KR20160065969A (enExample)
CN (1) CN105828831A (enExample)
AU (1) AU2014332346B2 (enExample)
BR (1) BR112016007816A2 (enExample)
CA (1) CA2926641A1 (enExample)
CL (1) CL2016000836A1 (enExample)
IL (1) IL244956B (enExample)
MX (1) MX2016004660A (enExample)
RU (1) RU2016112931A (enExample)
SG (1) SG11201602661PA (enExample)
WO (1) WO2015054006A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520162A (zh) * 2017-02-16 2019-11-29 凯尔格恩有限公司 水杨酸和肽的结合体

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6863362B2 (ja) * 2016-03-03 2021-04-21 不二製油株式会社 神経栄養因子の脳内分泌促進するための食品添加用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042561A2 (en) * 2003-10-31 2005-05-12 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods of use
WO2007011595A2 (en) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
US20130210726A1 (en) * 2012-02-10 2013-08-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
DE69738326T2 (de) 1996-07-12 2008-07-03 Mcgill University, Montreal Verbindungen und verfahren zur regulierung der zellanlagerung
WO2001053331A2 (en) 2000-01-24 2001-07-26 Adherex Technologies, Inc. Peptidomimetic modulators of cell adhesion
AU2002335657A1 (en) 2001-08-24 2003-03-10 Neuronz Biosciences, Inc. Neural regeneration peptide and methods for their use in treatment of brain damage
US7563862B2 (en) 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
AU2003293807A1 (en) * 2002-12-24 2004-07-22 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
WO2012006598A2 (en) * 2010-07-09 2012-01-12 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042561A2 (en) * 2003-10-31 2005-05-12 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods of use
WO2007011595A2 (en) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
US20130210726A1 (en) * 2012-02-10 2013-08-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520162A (zh) * 2017-02-16 2019-11-29 凯尔格恩有限公司 水杨酸和肽的结合体
CN110520162B (zh) * 2017-02-16 2023-02-17 凯尔格恩有限公司 水杨酸和肽的结合体

Also Published As

Publication number Publication date
IL244956B (en) 2019-10-31
SG11201602661PA (en) 2016-05-30
KR20160065969A (ko) 2016-06-09
EP3054967A4 (en) 2017-04-19
BR112016007816A2 (pt) 2017-12-05
WO2015054006A2 (en) 2015-04-16
AU2014332346B2 (en) 2019-01-24
CA2926641A1 (en) 2015-04-16
MX2016004660A (es) 2016-11-14
EP3054967A2 (en) 2016-08-17
WO2015054006A3 (en) 2015-06-04
JP2017501967A (ja) 2017-01-19
AU2014332346A1 (en) 2016-05-05
IL244956A0 (en) 2016-05-31
RU2016112931A (ru) 2017-11-16
CL2016000836A1 (es) 2016-09-16
RU2016112931A3 (enExample) 2018-06-20

Similar Documents

Publication Publication Date Title
US9511055B2 (en) Angiotensin in treating brain conditions
US20180050079A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
JP2018530590A (ja) 表皮水疱症の処置のための方法及び組成物
US20180221433A1 (en) Angiotensins in muscular dystrophy
KR20150065736A (ko) 안지오텐신의 경구 제형
US9333233B2 (en) Methods and compositions for the delayed treatment of stroke
CN105828831A (zh) 新型肽组合物
US20160296591A1 (en) Compositions and methods for treatment of bdnf-related conditions
US9133241B2 (en) Peptide compositions
WO2025122594A1 (en) Improved methods and compositions for the treatment of pemphigus or pemphigoid disease
TW202539635A (zh) 用於治療天疱瘡或類天疱瘡疾病的經改良方法及組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160803

WD01 Invention patent application deemed withdrawn after publication